Harminder Kaur, MD
Internal Medicine · Frederick, MDNPI 1083702799
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 61.3% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $5,648 and has fallen 94.4% since, to $314 in 2025. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $68.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$5K
- Takeda Pharmaceuticals U.S.A., Inc.$582
- AstraZeneca$564
- Lilly USA, LLC$292
- Otsuka America Pharmaceutical, Inc.$198
- Gilead$182
- plus $1K from 24 others
What the payments were for
- Consulting fees$4,79357%
- Travel & lodging$441%
- Food & beverage$3,53742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $5,136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $582 |
| AstraZeneca | 10 | $564 |
| Lilly USA, LLC | 11 | $292 |
| Otsuka America Pharmaceutical, Inc. | 2 | $198 |
| Gilead | 5 | $182 |
| Pfizer | 9 | $180 |
| Novartis | 4 | $179 |
| GSK | 3 | $161 |
| Axsome Therapeutics, Inc. | 1 | $119 |
| Teva Pharmaceuticals USA, Inc. | 1 | $113 |
| Biohaven Pharmaceuticals, Inc. | 4 | $87 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Johnson & Johnson(2 entities) | 3 | $67 |
| Eisai Inc. | 3 | $61 |
| Merck | 3 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Nabriva Therapeutics, PLC | 2 | $36 |
| Amgen | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Assertio Therapeutics, Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $24 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Bio Products Laboratory USA, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,374 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Frederick
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
- Matthew MintzBethesda$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.